Answer to Gerber et al. "Autosomal recessive pathogenic MSTO1 variants in hereditary optic atrophy".
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380
Informations de publication
Date de publication:
07 08 2023
07 08 2023
Historique:
revised:
17
05
2023
received:
02
05
2022
accepted:
17
05
2023
medline:
8
8
2023
pubmed:
11
7
2023
entrez:
11
7
2023
Statut:
ppublish
Résumé
Gal et al address the issues raised by Gerber et al and reiterate that patients in their study showed decreased Misato homolog 1 (MSTO1) mRNA and protein levels, but also confirm finding of Gerber et al that the mutation is in MSTO2p pseudogene. Whether MSTO2p variant contributes to the observed decrease in MSTO1 levels in patients remains unclear.
Identifiants
pubmed: 37431815
doi: 10.15252/emmm.202216251
pmc: PMC10405052
doi:
Substances chimiques
Cytoskeletal Proteins
0
Cell Cycle Proteins
0
MSTO1 protein, human
0
Types de publication
Letter
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16251Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2023 The Authors. Published under the terms of the CC BY 4.0 license.
Références
Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3375-3382
pubmed: 31081092
EMBO Mol Med. 2023 Aug 7;15(8):e16251
pubmed: 37431815
Oncotarget. 2017 Aug 4;8(35):59036-59047
pubmed: 28938616
EMBO Mol Med. 2023 Aug 7;15(8):e16090
pubmed: 37431816
EMBO Mol Med. 2017 Jul;9(7):967-984
pubmed: 28554942
World J Surg Oncol. 2022 Mar 26;20(1):95
pubmed: 35346226